In a significant development for the U.S. healthcare and pharmaceutical sectors, Eli Lilly and Novo Nordisk are reportedly in discussions with the Trump administration to lower the prices of their blockbuster obesity medications. The talks aim to make select doses available at prices as low as $149 per month in exchange for expanded coverage commitments from federal payers, according to reports by Endpoints News and The Wall Street Journal.

The discussions come as part of the administration’s broader efforts to drive down drug prices and increase patient access to essential therapies. If finalized, the agreements would mark a major step toward improving affordability of obesity treatments in the United States, where list prices for these drugs are currently much higher.

As part of the ongoing negotiations, Eli Lilly is also seeking a review voucher under the FDA’s recently introduced National Priority Review program to accelerate the approval timeline for its GLP-1 pill, orforglipron. Reports indicate the company is pushing for a one- to two-month review period, which would represent an unprecedented pace for FDA evaluation.

These developments follow a series of “most favored nation” pricing agreements struck between the Trump administration and major pharmaceutical companies over the past month. Industry leaders including Pfizer, AstraZeneca, and Merck KGaA’s EMD Serono have each reached pricing accords focused on improving affordability and securing tariff exemptions.

At an EMD Serono event in mid-October, President Donald Trump hinted that a landmark obesity drug deal was imminent, stating that “fat loss” medications could soon be available for around $150 per month. Shortly after, Centers for Medicare and Medicaid Services (CMS) Administrator Dr. Mehmet Oz confirmed that discussions with manufacturers were actively progressing.

If the agreements materialize this week as anticipated, they could set a new benchmark for collaboration between the U.S. government and the pharmaceutical industry, ensuring broader access to life-changing obesity treatments for millions of Americans.